Drug intelligence / Profile preview

OTX-201 (Orion Therapeutics)

Development stage: Preclinical
Lead developer: Orbital Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

OTX-201 is a preclinical-stage mRNA-based therapeutic being developed by Orion Therapeutics for the treatment of multiple cardiometabolic diseases. The drug candidate utilizes Orion's proprietary GENESYS™ (GENE-delivery System for Your Specificity) lipid nanoparticle (LNP) delivery platform, which is engineered to provide targeted delivery of genetic payloads to specific tissues. While the specific mRNA sequence and biological targets for OTX-201 have not been publicly disclosed, the program aims to leverage mRNA technology to express therapeutic proteins that address underlying drivers of cardiometabolic dysfunction. The program is currently in the discovery and preclinical development phase.

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on OTX-201 (Orion Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OTX-201 (Orion Therapeutics).

Explore the full profile